8-K

================================================================================



                     U.S. SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

       Date of Report (Date of earliest event reported): January 28, 2008

                              ONCOLOGIX TECH, INC.
           (Name of Small Business Issuer as Specified in Its Charter)

                                    0-15482
                             ----------------------
                            (Commission File Number)

            Nevada                                               86-1006416
 ------------------------------                               -----------------
(State or other jurisdiction of                              (I.R.S. Employer
 incorporation or organization)                              Identification No.)

                    3725 Lawrenceville-Suwanee Rd., Suite B-4
                                Suwanee, GA 30024
                     --------------------------------------
                    (Address of principal executive offices)

                                 (616) 977-9933
                            -------------------------
                           (Issuer's telephone number)

Check the appropriate box below if the Form 8-K is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:

[  ] Written communications pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)

[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
     CFR 240.14a-12)

[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))


================================================================================




Item 5.02     Departure of Directors or Principal Officers.

          On January 28, 2008, Dr. Andrew S. Kennedy, a director and Chief
Scientific and Medical Officer of the Registrant, resigned from the Board of
Directors and as an officer, such resignation to be effective on said date. Dr.
Kennedy expressed his disapproval of the structure of past financings made by
Company, and his view that the Registrant is in default with respect to its
license with the University of Maryland. He also questioned the propriety of
entertaining a proposal made by certain members of management to their proposed
purchase of the Registrant's assets and asked why funds apparently available to
them were not being invested in the Registrant. He also questioned why the
Registrant had not hired a financial advisor to assist the Registrant in
identifying acquisition candidates or financing sources.

          The response of the Registrant is that the financing structure was
based on sound business judgment and was in any event agreed to by Dr. Kennedy,
that the Registrant is not in default under the License, that in entertaining
the proposal in question the Board of Directors of the Registrant is acting
properly and in the best interests of the shareholders of the Registrant and
that there are sound reasons why no financial advisor has been hired by the
Registrant.

          The complete text of Dr. Kennedy's resignation, his stated reasons
therefor and the detailed response of the Registrant is set out in full in the
Exhibit filed with this Report.


Item 9.01     Financial Statements and Exhibits.

(d) Exhibits.

Exhibit             Title

99                  An email message from Andrew S. Kennedy, MD, dated January
                    28, 2008 and the Registrant's response thereto.


                                   SIGNATURES

          Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.


Dated: February 1, 2008                     ONCOLOGIX TECH INC.


                                            By:  /s/  Judy Lindstrom
                                               --------------------------------
                                                      Judy Lindstrom
                                                      Chairperson

                                            By:  /s/  Michael A. Kramarz
                                               --------------------------------
                                                      Michael A. Kramarz
                                                      Chief Financial Officer

EX-99

                                                                      EXHIBIT 99


                      Exhibit to Current Report on Form 8-K
                      -------------------------------------


Resignation by Andrew S. Kennedy, MD

The following is the text of an email message received by the officers of the
Registrant after the close of business on Monday, January 28, 2008:

To:  Board of Directors of Oncologix Tech Inc.

I cannot tell you all how disappointed and frustrated I am about where we are
with OCLG. Promises about financing were made when we agreed to merge JDA into
Oncologix. These promises were fundamental to our decision to merge and these
promises were broken. Not only were these promises broken, the financing that
was advanced was made on highly disadvantageous terms that severely limits our
flexibility. Who funds a pre-revenue research company with short-term debt?

Furthermore, those funding failures have resulted in OCLG breaching the license
agreement with U. of Maryland. And now I am being told that the best option open
to us is a transaction that must be approved immediately and would essentially
"give" the company away to existing senior management, accompanied by a highly
dilutive repricing of the outstanding convertible debt.

If Isonett has capital to exploit OCLG's technology why isn't it being invested
in OCLG?

In fact, these proposed transactions reek of self-dealing. This Board has made
only weak efforts at identifying other potential transactions and/or financing
sources that would better serve our shareholders. For example, we have made no
effort to retain a financial advisor to assist us in identifying financing
sources or acquisition candidates. We have made little or no effort at the Board
level to ensure that our actions will withstand scrutiny if challenged. I am
told that it is common practice in management buyouts for a special committee of
disinterested directors to be appointed with the ability to negotiate with the
management group and with the obligation to seek the best deal for shareholders.
It seems to me this Board is doing nothing that it should be doing and I am
extremely uncomfortable with the rush to deliver the company to management.

Please consider this communication notice of my resignation as an officer and
director of the company effective immediately.

Andrew S. Kennedy, MD, FACRO

The Registrant's response

     1.   Each financing transaction complained of was approved by the unanimous
          vote of all of the members of the Registrant's Board of Directors,
          including Dr. Kennedy. The choice of financing structure was
          influenced by a desire to limit dilution to existing shareholders and
          to accelerate funding for the development of the product technology
          acquired from JDA.

     2.   The Registrant has not received a notice of default from the
          University of Maryland and believes that there are no grounds for such
          a notice.




     3.   The Registrant does not now nor has it ever had any degree of control
          or influence over the investment decisions of Isonett (which has
          proposed to purchase the assets of the Registrant) or of any other
          person.

     4.   The Registrant rejects the characterization made in Dr. Kennedy's
          resignation letter that its efforts to identify "other potential
          transactions and/or financing sources" have been "weak'. Rather, the
          Registrant aggressively pursued all known sources, including those
          suggested by Dr. Kennedy himself. Notwithstanding those efforts, the
          only proposal received has been the one to which Dr. Kennedy objects.

     5.   The Registrant has not engaged an outside financial advisor
          principally because there are not sufficient funds to pay such a
          person and because of its concern that its assets might lose value
          during the time such an advisor would require to investigate the
          Registrant's business and seek financing sources not yet contacted by
          the Registrant.

     6.   The officers and directors characterized by Dr. Kennedy as the
          "management group" have not participated in any discussions held or
          decisions made by the Board of Directors with respect to their
          proposal. Furthermore, Ms Judy Lindstrom, the Chairman of the Board of
          Directors, who has no interest in the proposal, has been authorized to
          conduct discussions and negotiations with respect thereto subject to
          the final approval of all matters by a disinterested majority of the
          Board of Directors.

     7.   The Registrant rejects Dr. Kennedy's characterization of those
          discussions as constituting a "rush". Rather, that proposal has been
          subject to scrutiny and analysis to determine whether its consummation
          would be in the best interests of the shareholders of the Registrant,
          taking into consideration the present lack of any alternative
          proposals and the judgment of the Board of Directors that the value of
          the Registrant's assets will decline with the passage of time. However
          there are no binding agreements with respect to that proposal and no
          assurance that there ever will be.

     8.   Dr. Kennedy has himself proposed two alternatives, both of which have
          been pursued by the Registrant but there has been no indication of any
          interest by either of them.